A $63m VC Round Takes E-Scape Into Clinic With Alzheimer's, Parkinson's Drugs
Executive Summary
E-Scape's Series A cash will fund the development of small molecules targeting genetic drivers of neurodegenerative diseases, such as ApoE4 in Alzheimer's disease. The venture capital financing with big pharma backing will be used to take two programs into the clinic.